Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
One Percent Rule Checklist For Safer Forex Trading Risk 
BETHESDA, Md., April 10, 2017 -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces today that it has filed patent applications for IGC-501 in Canada, Israel, and Europe in support of its global cannabis-based combination therapy development initiatives.
IGC-501 is indicated for neuropathic pain. The pain market represents a significant component of the healthcare system and The Journal of Pain in September 2012 reported that the annual estimated national cost of pain ranges from $560 billion to $635 billion. In addition, abuse of prescription opioids is estimated to cost about $25 billion.
The international landscape embraces advancements in medical cannabis with countries like Germany, Israel and Canada being in the forefront. We aspire to bring our cannabis-based compounds to these markets and position ourselves for sustained growth. Canada’s recent introduction of legislation to legalize cannabis and Germany’s initiatives on medical cannabis are particularly encouraging on a global perspective. It should be noted that filing a patent does not guarantee that a patent will be issued in the future.
“We continue to strengthen our IP position in cannabis-based combination therapies and have progressed to include global patent filings. IGC is committed to addressing high potential international markets as a first mover in this emerging segment of cannabis-based combination therapy pharmaceuticals,” concludes Ram Mukunda, CEO.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see risk factors discussed in India Globalization Capital, Inc.’s Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
